RT Book, Section
A1 Wetzel, Dawn M.
A1 Phillips, Margaret A.
A2 Brunton, Laurence L.
A2 Knollmann, Björn C.
SR Print(0)
ID 1193241220
T1 Chemotherapy of Protozoal Infections: Amebiasis, Giardiasis, Trichomoniasis, Trypanosomiasis, Leishmaniasis, and Other Protozoal Infections
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264258079
LK accessmedicine.mhmedical.com/content.aspx?aid=1193241220
RD 2024/04/18
AB Humans  host  a  wide  variety  of  protozoal  parasites  that  can  be  transmitted  by  insect  vectors,  directly  from  other  mammalian  reservoirs,  or  from  one  person  to  another.  The  immune  system  plays  a  crucial  role  in  protecting  against  the  pathological  consequences  of  many  protozoal  infections.  Thus,  opportunistic  infections  with  protozoa  are  prominent  in  patients  with  suppressed  or  underdeveloped  immune  systems,  such  as  infants,  individuals  with  cancer,  transplant  recipients,  those  receiving  immunosuppressive  drugs  or  extensive  antibiotic  therapy,  and  persons  with  advanced  human  immunodeficiency  virus  (HIV)  infection.  Because  effective  vaccines  are  unavailable,  chemotherapy  has  been  the  only  practical  way  to  both  treat  infected  individuals  and  reduce  transmission.  Satisfactory  agents  for  treating  important  protozoal  infections  such  as  African  trypanosomiasis  (sleeping  sickness)  and  chronic  Chagas  disease  still  are  lacking.  Many  effective  antiprotozoal  drugs  are  toxic  at  therapeutic  doses;  this  problem  is  exacerbated  by  increasing  drug  resistance  (McCarthy  et  al.,  2020).  For  a  list  of  drugs  and  doses  used  to  treat  these  diseases,  see  Kimberlin  et  al.  (2018)  and  McCarthy  et  al.  (2020).